Biocon, Mylan receives approval for biosimilar version of Herceptin
USFDA has given approval to Mylan’s Ogivri, which is a biosimilar of cancer drug Herceptin, co-developed with Biocon. Trastuzumab is the generic name of Herceptin. Ogivri has received...
